A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2018
Price : $35 *
At a glance
- Drugs Mirabegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Adverse reactions
- Acronyms PREFER
- Sponsors Astellas Pharma
- 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society.
- 22 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 01 Jul 2015 Planned End Date changed from 1 Jan 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.